UK To Fund ‘Artificial Pancreas’ Technology, But Only For Companies That Cut Prices
The UK’s health technology assessment organization is in favor of funding hybrid closed loop systems for certain people with type 1 diabetes, but only if companies agree to provide such products at more “cost-effective” prices.
You may also be interested in...
Abbott’s flagship CGM, the FreeStyle Libre 3, will soon become available in the UK through the National Health Service as part of a hybrid closed-loop system utilizing Ypsomed and CamDiab’s technologies.
In this edition of the Medtech Monthly podcast, Medtech Insight editor Reed Miller talks to UK-based reporter Barnaby Pickering to get a overview of the highly competitive diabetes tech and future of this dynamic, consumer-centric market.
In this edition of Medtech Monthly, Robert Gabbay, chief scientific and medical officer for the American Diabetes Association talked to Medtech Insight about diabetes tech, where it's headed, and what it could mean for preventative care.